Business Model: Initially a generic pharmaceutical company relying on reverse-engineering patented drugs, Cipla shifted post-2005 due to stricter patent laws. It now emphasizes organic growth, selective strategic alliances, and increased exports to Western markets, alongside R&D for niche products. The company operates two segments: Pharmaceuticals (core revenue driver) and New Ventures (consumer healthcare, biosimilars).
Financials: Cipla reported ₹25,774 crore in revenue and ₹4,154 crore in net profit in FY24, with a 25.1% CAGR in profit growth over five years. It maintains low debt (₹559 crore) and a healthy dividend payout of 22%.
Strategic Initiatives: Cipla has expanded through acquisitions (e.g., Ivia Beaute’s cosmetics business for ₹130 crore in 2024) and innovation, launching products like Spirofy (wireless spirometer) and CIPREMI (Remdesivir). Its U.S. subsidiary, Cipla USA, drives growth in complex generics, while Cipla Health Limited strengthens its consumer healthcare portfolio.
Challenges: Cipla faces regulatory hurdles, modest sales growth (9.51% over five years), and competition from global giants. Promoter holding has decreased by 4.43% in recent years, signaling potential vulnerabilities.
Latest News on Cipla
HOSMAC has designed Cipla’s Breathefree Lung Wellness Centre in Mumbai, focusing on adaptive reuse and a wellness-centric approach, as reported by Prop News Time.
HOSMAC, a renowned healthcare design and consulting firm, has successfully designed Cipla’s Breathefree Lung Wellness Centre in Mumbai. The centre is a testament to HOSMAC’s expertise in creating healthcare facilities that prioritize patient-centric care and wellness. The design of the centre emphasizes adaptive reuse, transforming an existing building into a state-of-the-art lung wellness centre.
The Breathefree Lung Wellness Centre is a 5,000-square-foot facility located in the heart of Mumbai. The centre offers a comprehensive range of services, including lung function testing, pulmonary rehabilitation, and patient education. The design of the centre is centered around the concept of “wellness-led care,” which focuses on promoting overall well-being and preventive care rather than just treating illnesses.
HOSMAC’s design team worked closely with Cipla to create a space that is both functional and aesthetically appealing. The centre features a modern and sleek design, with ample natural light and ventilation. The interior design elements, including the color scheme and furniture, are carefully selected to create a calming and soothing atmosphere, conducive to patient recovery and wellness.
One of the key highlights of the centre is its emphasis on adaptive reuse. The existing building was transformed into a lung wellness centre, minimizing waste and reducing the environmental impact of the project. The design team worked closely with the existing structure, incorporating sustainable design principles and materials to create a energy-efficient and eco-friendly facility.
The Breathefree Lung Wellness Centre is equipped with cutting-edge technology and medical equipment, ensuring that patients receive the best possible care. The centre also features a team of experienced healthcare professionals, including pulmonologists, physiotherapists, and nutritionists, who work together to provide comprehensive care to patients.
The centre’s design and services are tailored to meet the specific needs of patients with lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The centre offers a range of programs and services, including pulmonary rehabilitation, smoking cessation, and patient education, to help patients manage their condition and improve their overall quality of life.
Overall, the Breathefree Lung Wellness Centre is a shining example of HOSMAC’s expertise in designing healthcare facilities that prioritize patient-centric care and wellness. The centre’s emphasis on adaptive reuse, wellness-led care, and sustainable design principles makes it a unique and innovative healthcare facility in Mumbai. With its state-of-the-art technology, experienced healthcare professionals, and comprehensive range of services, the centre is poised to become a leading destination for lung wellness and care in the region.
Several major Indian pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti, have issued recalls for certain medications in the United States market.
Several major pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti Pharmaceuticals, are recalling various products in the US due to manufacturing issues, according to recent US FDA enforcement reports. The recalls are primarily related to problems with impurities, quality control, and production processes.
Sun Pharma is recalling over 24,000 bottles of Fluocinolone Acetonide topical solution and Clindamycin Phosphate topical solution due to out-of-specification results for impurities and assay. Cipla is recalling more than 15,000 syringes of Lanreotide Injection, used to treat a rare hormonal condition, due to production issues at its Greek manufacturing partner, Pharmathen. The production of Lanreotide has been temporarily paused to address quality concerns, resulting in limited supply.
Additionally, Cipla is recalling over 92,000 tubes of Diclofenac Sodium Topical Gel due to failed pH specifications. Graviti Pharmaceuticals is recalling over 4,000 bottles of Furosemide Tablets due to the presence of a foreign substance. Zydus Pharmaceuticals is recalling over 22,000 bottles of Icosapent Ethyl capsules due to oxidation caused by leakage, which may lead to inconsistent therapeutic effects and increased gastrointestinal side effects.
These recalls highlight the importance of quality control and manufacturing standards in the pharmaceutical industry. The FDA’s enforcement actions aim to ensure that products meet strict safety and efficacy standards to protect public health. The recalls may result in temporary shortages of these products, and patients are advised to consult their healthcare providers for alternative treatments.
The recalls also underscore the need for pharmaceutical companies to maintain robust quality control systems and adhere to good manufacturing practices (GMPs) to prevent such issues. The companies involved are taking corrective actions to address the problems and prevent future occurrences. The FDA will continue to monitor the situation and take further action if necessary to ensure the safety and efficacy of pharmaceutical products in the US market.
Cipla Collaborates with ImmunoACT to Introduce CAR-T Cell Therapy for Blood Cancer Treatment in African Markets.
Cipla, a leading pharmaceutical company, has partnered with ImmunoACT, a biotech firm, to launch CAR-T cell therapy for the treatment of blood cancers in Africa. This collaboration aims to make this innovative and potentially life-saving treatment more accessible to patients in the region.
CAR-T cell therapy is a form of immunotherapy that involves extracting a patient’s T cells, genetically modifying them to recognize and attack cancer cells, and then reinfusing them back into the body. This treatment has shown remarkable success in treating certain types of blood cancers, including leukemia and lymphoma.
The partnership between Cipla and ImmunoACT will enable the development and commercialization of CAR-T cell therapy in Africa, where access to such treatments is currently limited. Cipla will leverage its extensive distribution network and manufacturing capabilities to support the launch of the therapy, while ImmunoACT will provide its expertise in CAR-T cell technology and clinical development.
The launch of CAR-T cell therapy in Africa is a significant milestone, as it has the potential to transform the treatment landscape for blood cancers in the region. Currently, many patients in Africa lack access to effective treatments for these diseases, resulting in poor outcomes and high mortality rates. The introduction of CAR-T cell therapy is expected to improve treatment options and outcomes for these patients.
The partnership also highlights the growing importance of collaboration between pharmaceutical companies, biotech firms, and healthcare providers in addressing the complex challenges of cancer treatment in Africa. By working together, these stakeholders can pool their resources, expertise, and knowledge to develop and deliver innovative treatments that can make a meaningful difference in the lives of patients.
In addition to improving treatment options, the launch of CAR-T cell therapy in Africa is also expected to drive awareness and education about blood cancers and the importance of early diagnosis and treatment. This, in turn, can help to reduce stigma and promote a better understanding of these diseases, ultimately leading to improved health outcomes for patients and their families.
Overall, the partnership between Cipla and ImmunoACT to launch CAR-T cell therapy in Africa represents a significant step forward in the fight against blood cancers in the region. By making this innovative treatment more accessible, the partners aim to improve treatment options, outcomes, and quality of life for patients, while also driving awareness and education about these diseases.
US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth
The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue and margin driver for Indian drugmakers such as Dr Reddy’s Laboratories, Cipla, Zydus Lifesciences, and Sun Pharma. However, with the patent expiry in January 2026, these companies will have to offload their remaining quotas, leading to a decline in sales.
Analysts expect a sector-wide decline in earnings before interest, taxes, depreciation, and amortization (Ebitda) margins by 150 basis points year-on-year, with companies such as Dr Reddy’s, Cipla, and Zydus Lifesciences likely to be affected. The decline in Revlimid sales will be a significant contributor to this margin pressure, with prices expected to erode sharply as players look to offload remaining quotas. Additionally, other factors such as increased generic price competition in the US market, higher research and development (R&D) expenses, and rising selling, general, and administrative (SG&A) costs will also weigh on margins.
Despite these challenges, analysts remain optimistic about the sector’s overall revenue growth, with expectations of 8-11% growth driven by steady domestic growth and traction in other markets. Domestic sales are projected to outpace the broader Indian pharmaceutical market’s 10.1% growth, with the chronic segment showing particular strength. Companies such as Lupin, Sun Pharma, and Cipla are expected to see growth driven by their innovative medicines portfolios and recent launches.
The US market, however, is expected to be a challenge, with overall US sales projected to decline by 4% quarter-on-quarter due to lower Revlimid sales. Excluding Revlimid, US generic sales are forecast to grow by 2% quarter-on-quarter, driven by volume expansion in existing products and the benefits from recent launches. Overall, while the loss of Revlimid patent exclusivity will be a significant challenge for Indian pharmaceutical companies, their domestic growth and innovative medicines portfolios are expected to provide some resilience and drive overall revenue growth.
Cipla collaborates with Stempeutics to introduce revolutionary stem cell treatment for osteoarthritis of the knee.
Cipla, a leading pharmaceutical company, has partnered with Stempeutics, a stem cell therapy company, to launch a stem cell-based treatment for knee osteoarthritis in India. This innovative therapy aims to provide relief to patients suffering from knee osteoarthritis, a degenerative joint disease that affects millions of people worldwide.
Knee osteoarthritis is a common condition that causes pain, stiffness, and limited mobility in the knee joint. Current treatment options, such as painkillers, physical therapy, and surgery, often provide only temporary relief and can have significant side effects. Stem cell therapy, on the other hand, offers a promising alternative by using the body’s own cells to repair and regenerate damaged tissues.
The stem cell therapy launched by Cipla and Stempeutics uses mesenchymal stem cells, which are derived from the patient’s own bone marrow or adipose tissue. These cells have the ability to differentiate into various cell types, including cartilage cells, and can help repair damaged tissues in the knee joint. The therapy involves a simple, minimally invasive procedure, where the stem cells are injected into the affected knee joint.
According to the companies, this stem cell therapy has shown promising results in clinical trials, with significant improvements in pain reduction, functional ability, and quality of life. The therapy is also said to be safe, with minimal side effects reported.
The partnership between Cipla and Stempeutics marks a significant milestone in the field of regenerative medicine in India. Cipla’s extensive distribution network and marketing capabilities will help make this innovative therapy accessible to a wider audience, while Stempeutics’ expertise in stem cell technology will ensure the highest quality of the therapy.
The launch of this stem cell therapy is expected to revolutionize the treatment of knee osteoarthritis in India, providing new hope to patients who have been suffering from this debilitating condition. With its potential to repair and regenerate damaged tissues, this therapy may also reduce the need for surgical interventions and improve the overall quality of life for patients. As the field of regenerative medicine continues to evolve, partnerships like this one between Cipla and Stempeutics are likely to play a significant role in shaping the future of healthcare in India.
Stock Market Updates for Cipla
Recent Updates
Cipla inaugurates a specialized lung health diagnostic facility in the nation’s capital, Delhi.
Cipla, a leading pharmaceutical company, has launched a dedicated lung health diagnostics centre in Delhi, India. This initiative is part of the company’s efforts to reimagine Indian healthcare and provide comprehensive care to patients with respiratory diseases. The centre is equipped with state-of-the-art facilities and technology to provide accurate diagnoses and treatment for various lung-related conditions.
The lung health diagnostics centre is designed to cater to the growing burden of respiratory diseases in India, which is one of the leading causes of morbidity and mortality in the country. The centre will offer a range of diagnostic services, including pulmonary function tests, spirometry, and imaging services such as X-rays and CT scans. The centre will also provide consultation services with specialist doctors and offer treatment options for patients with lung diseases.
Cipla’s initiative is a significant step towards addressing the shortage of specialized healthcare facilities for lung diseases in India. The company aims to provide accessible and affordable healthcare services to patients, particularly in rural and underserved areas. The centre will also serve as a hub for awareness and education on lung health, providing patients and caregivers with information on disease management and prevention.
The launch of the lung health diagnostics centre is in line with Cipla’s commitment to improving healthcare outcomes in India. The company has been working towards expanding access to healthcare services, particularly in the areas of respiratory care, oncology, and infectious diseases. Cipla’s efforts are focused on providing innovative and affordable solutions to patients, and the launch of the lung health diagnostics centre is a significant milestone in this journey.
The centre is expected to benefit a large number of patients in Delhi and surrounding areas, providing them with access to specialized care and treatment for lung diseases. Cipla’s initiative is also expected to raise awareness about the importance of lung health and the need for early diagnosis and treatment of respiratory diseases. With the launch of the lung health diagnostics centre, Cipla is reiterating its commitment to improving healthcare outcomes in India and providing comprehensive care to patients with respiratory diseases.
Cipla Inaugurates India’s Pioneer Comprehensive Lung Wellness Facility in Delhi
Cipla, a leading pharmaceutical company, has launched India’s first fully integrated Breathefree Lung Wellness Center in Delhi. The center, located in Lajpat Nagar, offers a comprehensive range of services, including over 60 diagnostic tests, pulmonary rehabilitation, nutrition support, and smoking cessation counseling. The goal of the center is to address the critical gap in India’s respiratory care ecosystem by providing advanced, standardized lung diagnostics at an affordable price.
The launch of the center is timely, given India’s growing burden of chronic respiratory diseases, which affects an estimated 90 million people. Many patients remain undiagnosed or misdiagnosed due to limited access to specialized diagnostic infrastructure and high-quality pulmonary testing. The center’s diagnostic tests cover various aspects of lung health, including lung physiology, microbiology, immunology, blood chemistry, and radiology.
In addition to diagnostics, the center provides pulmonary rehabilitation, nutritional support, and smoking cessation counseling. The center will also function as a training and certification hub for healthcare professionals and facilitate research in respiratory sciences. According to Achin Gupta, Global COO of Cipla, the center addresses a critical gap in the diagnostic landscape and aims to make high-quality, standardized lung diagnostics accessible to doctors and patients across India.
The launch of the center coincides with Cipla’s 90th anniversary year, signaling the company’s commitment to expanding beyond pharmaceuticals into diagnostics and patient-management services. The center’s launch is also significant, given Delhi’s recent severe air pollution, which has exacerbated respiratory problems. With the Breathefree Lung Wellness Center, Cipla hopes to improve early diagnosis, treatment, and overall respiratory health for patients across India.
The center’s services include spirometry, oscillometry, DLCO, body plethysmography, FeNO, CPET, sleep studies, X-rays, and CT scans, all conducted by trained technicians following globally recognized protocols. The center’s team, led by Chief Medical Officer Jaideep Gogtay, aims to provide accurate and timely diagnosis, which is key to reducing hospitalization and improving patient outcomes. Overall, the Breathefree Lung Wellness Center is a significant step towards addressing India’s growing respiratory health needs and providing accessible, high-quality lung diagnostics and care.
Indian pharmaceutical companies Cipla, Natco, Hetero, and Annora have secured major contracts to supply generic drugs to the Chinese market.
Cipla, Natco, Hetero, and Annora, four prominent Indian pharmaceutical companies, have secured significant contracts to supply generic drugs to China. This development marks a major breakthrough for Indian pharmaceutical companies in the Chinese market. The contracts were awarded after a rigorous bidding process, and the selected companies will supply a range of generic drugs to China’s government-backed procurement program.
The contracts are a testament to the growing reputation of Indian pharmaceutical companies as reliable suppliers of high-quality, affordable generic medicines. Cipla, Natco, Hetero, and Annora have demonstrated their capabilities in manufacturing and supplying a wide range of generic drugs, including those for treating diseases such as cancer, HIV, and hepatitis.
The Chinese government’s decision to award these contracts to Indian companies is expected to have a significant impact on the global pharmaceutical landscape. It underscores the growing importance of India as a hub for generic drug manufacturing and highlights the country’s capabilities in producing high-quality, affordable medicines.
The contracts are also expected to boost India’s pharmaceutical exports to China, which have been growing steadily in recent years. India’s pharmaceutical exports to China were valued at over $100 million in 2020, and this figure is expected to increase significantly with the awarding of these contracts.
The winning companies have expressed their delight at being awarded the contracts and have committed to delivering high-quality products to the Chinese market. Cipla, for example, has stated that it will supply a range of generic drugs, including those for treating respiratory diseases, while Natco will supply generic versions of cancer and HIV medicines.
The awarding of these contracts is also seen as a major vote of confidence in the Indian pharmaceutical industry, which has faced challenges in recent years, including regulatory issues and quality concerns. The contracts demonstrate that Indian companies can meet the stringent quality standards required by the Chinese market and are capable of competing with global pharmaceutical majors.
Overall, the awarding of these contracts to Cipla, Natco, Hetero, and Annora is a significant development for the Indian pharmaceutical industry, and it is expected to have a positive impact on the country’s pharmaceutical exports and reputation as a hub for generic drug manufacturing.
Eli Lilly’s Mounjaro achieves ₹1 billion in monthly sales in India’s pharma market through partnership with Cipla.
Eli Lilly’s diabetes medication, Mounjaro, has achieved unprecedented success in India’s pharmaceutical market, crossing ₹1 billion in monthly sales. This remarkable feat is a result of the company’s strategic partnership with Cipla, a leading Indian pharmaceutical firm. Mounjaro, which is also known as tirzepatide, is a revolutionary treatment for type 2 diabetes, offering improved glycemic control and weight loss benefits.
The partnership between Eli Lilly and Cipla has enabled the widespread distribution of Mounjaro across India, making it accessible to a large patient population. Cipla’s extensive network and expertise in the Indian market have played a crucial role in the medication’s success. The company’s efforts have helped to raise awareness about Mounjaro’s benefits among healthcare professionals and patients, driving demand and contributing to its impressive sales figures.
Mounjaro’s success in India is significant, given the country’s large and growing diabetic population. According to the International Diabetes Federation, India has over 77 million people living with diabetes, and this number is expected to increase to 134 million by 2045. The need for effective and innovative treatments like Mounjaro is therefore critical, and Eli Lilly’s partnership with Cipla has helped to address this need.
The ₹1 billion monthly sales milestone is a testament to the strong demand for Mounjaro in India and the effectiveness of the partnership between Eli Lilly and Cipla. The medication’s success is expected to continue, driven by its clinical benefits, increasing awareness, and the growing burden of diabetes in the country.
The partnership between Eli Lilly and Cipla is also a notable example of how global pharmaceutical companies can successfully collaborate with local partners to expand their presence in emerging markets. By leveraging Cipla’s expertise and network, Eli Lilly has been able to navigate the complex Indian market and achieve remarkable success with Mounjaro.
In conclusion, Mounjaro’s achievement of ₹1 billion in monthly sales in India is a significant milestone, driven by the effective partnership between Eli Lilly and Cipla. The medication’s success highlights the growing demand for innovative treatments in India’s pharmaceutical market and demonstrates the potential for global companies to achieve success in emerging markets through strategic partnerships. As the burden of diabetes continues to grow in India, Mounjaro is likely to play an increasingly important role in addressing this major public health challenge.